








Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

Correction to: *Nature Medicine* <https://doi.org/10.1038/s41591-023-02583-2>, published online 16 October 2023.

<https://doi.org/10.1038/s41591-023-02661-5>

Published online: 3 November 2023

John M. Kirkwood , Michele Del Vecchio, Jeffrey Weber, Christoph Hoeller , Jean-Jacques Grob, Peter Mohr, Carmen Loquai, Caroline Dutriaux, Vanna Chiarion-Sileni, Jacek Mackiewicz, Piotr Rutkowski, Petr Arenberger, Gaelle Quereux, Tarek M. Meniawy , Paolo A. Ascierto , Alexander M. Menzies, Piyush Durani, Maurice Lobo, Federico Campigotto, Brian Gastman & Georgina V. Long 

In the version of the article initially published, John M. Kirkwood was presented in the author list without a middle initial. The error has been corrected in the HTML and PDF versions of the article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

Publisher Correction: Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary

Correction to: *Nature Medicine* <https://doi.org/10.1038/s41591-023-02482-6>, published online 7 August 2023.

<https://doi.org/10.1038/s41591-023-02693-x>

Published online: 15 November 2023

Intae Moon , Jaclyn LoPiccolo, Sylvan C. Baca, Lynette M. Sholl , Kenneth L. Kehl , Michael J. Hassett, David Liu , Deborah Schrag & Alexander Gusev 

In the version of the article initially published, in Table 1, five cancer types were mistakenly placed under incorrect groups. Invasive breast carcinoma (BRCA), Colorectal adenocarcinoma (COADREAD), Prostate adenocarcinoma (PRAD), Melanoma (MEL) and Gastrointestinal stromal tumor (GIST) now stand as individual cancer groups. In the fifth paragraph of the introduction, the fifth sentence has been updated to read “We applied this classifier, named OncoNPC, to 971 tumor samples from patients with CUP with clinical follow-up at Dana-Farber Cancer Institute (DFCI).” Additionally, Supplementary Data 3 and 5 were interchanged. These changes have been made in the HTML and PDF versions of the article.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2023